To estimate the years lived with disability, we used life tables adjusted for sex, age, and geographic region, and we estimated the years of life lived from the time of microbiologic cure to predicted death [19].
Secondary endpoints included microbiologic cure, duration of mechanical ventilation, length of stay, and hospital mortality.
Secondary endpoints included microbiologic cure, duration of mechanical ventilation, length of stay, all-cause hospital mortality and MDR-GN pneumoniattributablele mortality.
No significant difference was observed between the two groups in terms of crude mortality, VAP attributed mortality, microbiologic cure, or duration of ICU stay.
However, retrospective evaluation of microbiologic cure is not optimal as a determinant of therapeutic efficacy due to the bias inherent to repeat respiratory cultures.
An additional factor limiting the utility of microbiologic cure as an outcome measure is the inherent challenge of differentiating bacterial pneumonia from colonization following the initial infection [ 15].
The value of the 24 h static dose was a fAUC0-24h/MIC of 40.84 h and when the ratio reached 91.08 h, rates of microbiologic cure approached 50%%.
Significant heterogeneity across the different infectious syndromes was detected for outcomes of microbiologic cure (I2 = 71%, P value < 0.0001) but not for clinical cure (I2 = 0%, P = 0.68) or survival (I2 = 0%, P = 0.64).
From all trials, we extracted available data on outcomes of clinical cure, microbiologic cure, and survival for the overall groups of patients receiving shorter- and longer-duration antibiotic therapy.
In our primary analysis, though, we examined these three outcomes (clinical cure, microbiologic cure, and survival) among the subgroup of patients with bacteremia in each treatment arm.
